Biosimilars
14 articles on Biosimilars, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic, Mounjaro & More: Bridging the Global Gap for Cheaper Biologics
While generics have revolutionized drug affordability, newer biologics like those used for weight loss and diabetes face unique challenges. A new study reveals how varying international regulations are slowing the adoption of affordable biosimilars, impacting patient access and costs.
6 min read
Why Semaglutide and Tirzepatide Are Redefining Weight Loss Culture
Prescriptions for weight loss drugs have tripled since 2020. Discover the science, social impact, and practical tips for navigating the GLP-1 era safely.
6 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution Reshaping Health
The GLP-1 analogue market is experiencing unprecedented growth, transforming from diabetes treatments to comprehensive cardiometabolic solutions. Discover the key drivers, leading medications, and future innovations shaping this dynamic field.
9 min read
Generic GLP-1s: Hope for Affordable Weight Loss & Diabetes Care?
As brand-name GLP-1 medications such as Ozempic and Wegovy become increasingly sought after for weight loss and diabetes management, many Canadians face significant cost barriers. The anticipation surrounding the approval of generic semaglutide offers a beacon of hope for improved accessibility and affordability. This article delves into the current landscape, patient stories, and expert insights on the journey towards more accessible peptide therapies.
7 min read
Pharmacists' Key Role in Helping Patients Maximize GLP-1 Drugs
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are emerging as crucial allies in ensuring treatment success. According to the American Society of Health-System Pharmacists, these experts help navigate costs, side effects, and lifestyle integration. This guide explores their vital role in maximizing benefits and minimizing risks.
5 min read
Zydus, Lupin Partner to Launch Ozempic Rival Semaglutide in India
Zydus Lifesciences and Lupin are teaming up to bring Semaglutide injection to India, positioning it as a rival to Ozempic for type 2 diabetes and chronic weight management. Marketed by Zydus with a user-friendly reusable pen, this GLP-1 therapy offers new options for adults with poor glycemic control or obesity-related conditions. Here's what patients need to know about this launch.
5 min read
China Biotech Targets 2028 Trials for Semaglutide Nasal Spray Like Wegovy
A Shanghai-based biotech is developing a nasal spray version of semaglutide, the key ingredient in Novo Nordisk's Wegovy, with global clinical trials targeted for completion by 2028. This experimental weight-management spray promises lower costs than tablets and better suitability for long-term use. As Novo's patent nears expiration in China, competition heats up in the booming GLP-1 market.
4 min read
Roche CT-388: GLP-1/GIP Shot Rivals Zepbound in Phase 2
Roche is advancing CT-388, a dual GLP-1/GIP agonist, after Phase 2 results showed impressive weight loss comparable to Eli Lilly's Zepbound. With the obesity market booming, can this injectable stand out against Wegovy and emerging orals? Dive into the data and what it means for patients.
4 min read
GLP-1 Market Boom to $299B by 2033: Drugs & Insights
The GLP-1 analogues market is surging from $62.81B in 2024 to $299.08B by 2033, driven by rising diabetes and obesity rates. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound lead with proven efficacy in glycemic control and weight loss. This guide breaks down the science, market trends, and what patients should know.
4 min read
Scotland GLP-1 Costs Surge: Mounjaro Price Hike Impact
Scotland's NHS spending on GLP-1 weight-loss injections like Mounjaro has skyrocketed to nearly £3 million monthly, fueled by surging prescriptions and a sudden Mounjaro price hike tied to US policy. These drugs offer profound benefits beyond weight loss, reducing risks of heart disease and more. Here's what patients need to know about access, costs, and real-world impact.
4 min read
Why Ozempic & GLP-1s Cost More in the US: A Guide
A 54-year-old father walked away from his $997 Ozempic prescription due to sky-high costs. GLP-1 medications like Ozempic and Mounjaro offer transformative benefits for diabetes and obesity, yet US prices make them unaffordable for millions. This guide breaks down the pricing crisis, clinical value, and paths to reform.
4 min read
FDA Approvals for 2025
In 2025, the FDA approved 46 novel therapeutic agents from its Center for Drug Evaluation and Research, marking a slight dip from the five-year average but remaining above historical norms. Cancer led approvals, with advancements in modalities like kinase inhibitors and gene therapies. The year also introduced new programs and faced staffing challenges under changing leadership.
13 min read
GLP-1 Agonist Market Surge: A Metabolic Shift Transforming Diabetes Treatment and Global Obesity Management
The GLP-1 agonist market is undergoing significant expansion, fundamentally changing how Type 2 Diabetes and obesity are addressed globally. This drug class, initially for glycemic control, has become a key therapeutic option for weight management and cardiovascular risk reduction. The rising popularity of these drugs has sparked a pharmaceutical boom, with focus shifting to advanced agonists offering even greater metabolic advantages.
4 min read
Sandoz CEO Predicts Semaglutide Biosimilars Entering Canadian Market in Q1 or Q2
Richard Saynor, CEO of Sandoz, expects biosimilars referencing semaglutide to be available in Canada in early 2026. This projection comes as Novo Nordisk's patent protection for the drug nears its end. Sandoz intends to capitalize on the commercial opportunity as soon as regulatory approval is granted.
3 min read